Biodesix Inc., a diagnostic solutions company, announced its financial results for the first quarter ended March 31, 2025. The company reported total revenue of $18.0 million, reflecting a 21% increase compared to the same period in 2024. This growth was driven by a rise in Diagnostic Testing revenue, which reached $16.3 million, an 18% increase, primarily due to an increase in total tests delivered. Additionally, Development Services revenue rose by 61% to $1.7 million. The gross margin for Q1 2025 was $14.3 million, or 79.4% of total revenue, up from 78.6% in the previous year, attributed to advancements in Diagnostic testing and improvements in testing workflows. Operating expenses, excluding direct costs and expenses, increased by 3% to $23.4 million, mainly due to a $900 thousand rise in Research and Development costs. Biodesix reported a net loss of $11.1 million for the first quarter, an improvement of 18% over the same period last year. Adjusted EBITDA showed a loss of $6.2 million, improving by 11% from the prior year. The company has updated its 2025 revenue guidance to a range of $80-85 million and expects to achieve Adjusted EBITDA positivity in the fourth quarter. Following the first quarter, Biodesix strengthened its cash position by drawing $10 million from its term loan facility with Perceptive Advisors, boosting its pro forma cash balance to $27.6 million.